Rita Dorantes-Heredia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rita Dorantes-Heredia has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Angélica D Hidalgo-Maldonado
Hospital Médica Sur , Puente de Piedra 150, 14050 Mexico City
1 shared publicationBeatriz Barranco-Fragoso
Department of Gastroenterology, National Medical Center “20 de Noviembre”, ISSSTE, Mexico City, Mexico
1 shared publication- Edson Escandón-Villalobos
Department of General Surgery, Hospital Médica Sur , Puente de Piedra 150, 14050 Mexico City
1 shared publication - Gonzalo Torres-Villalobos
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
1 shared publication - Irving Fuentes-Calvo
Epilepsy Clinic and Clinical Epileptology Fellowship, National Institute of Neurology and Neurosurgery “Manuel Velasco Suarez” and Faculty of Medicine, UNAM, Mexico City
1 shared publication - Jose H Flores-Arredondo
The Methodist Hospital Research Institute, The Methodist Hospital at Houston, Houston, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 2 July 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (7) , rjaf585
Complicated appendicitis as a rare presentation of Burkitt’s lymphoma: a case report
Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that rarely involves the appendix and may mimic acute appendicitis, complicating preoperative diagnosis. In the context of nonoperative management for appendicitis, such malignancies risk being overlooked. A 32-year-old immunocompetent male presented with right upper quadrant pain, leukocytosis, cholestatic liver profile, and a hepatic lesion on imaging. Positron emission tomography-computed tomography (PET-CT) showed intense fluorodeoxyglucose uptake in the colon, liver, and peritoneum. Laparoscopy revealed an enlarged appendix (15 × 3 cm) with abscess; appendectomy was performed. Histopathology confirmed BL with a ‘starry sky’ pattern and Ki-67 of 95%. Appendiceal BL, though rare, should be suspected in atypical or complicated appendicitis, even without classic risk factors. Histopathological examination of appendectomy specimens is crucial. Surgery, even when not oncologic in intention, may lead to early cancer detection and timely systemic treatment, improving outcomes.
- 2 July 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (7) , rjaf585
Open AccessComplicated appendicitis as a rare presentation of Burkitt’s lymphoma: a case report
Burkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that rarely involves the appendix and may mimic acute appendicitis, complicating preoperative diagnosis. In the context of nonoperative management for appendicitis, such malignancies risk being overlooked. A 32-year-old immunocompetent male presented with right upper quadrant pain, leukocytosis, cholestatic liver profile, and a hepatic lesion on imaging. Positron emission tomography-computed tomography (PET-CT) showed intense fluorodeoxyglucose uptake in the colon, liver, and peritoneum. Laparoscopy revealed an enlarged appendix (15 × 3 cm) with abscess; appendectomy was performed. Histopathology confirmed BL with a ‘starry sky’ pattern and Ki-67 of 95%. Appendiceal BL, though rare, should be suspected in atypical or complicated appendicitis, even without classic risk factors. Histopathological examination of appendectomy specimens is crucial. Surgery, even when not oncologic in intention, may lead to early cancer detection and timely systemic treatment, improving outcomes.
- Open Access
- 8 August 2022
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 28, e937528-1-e937528-11
Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity
Metabolic dysfunction-associated fatty liver disease (MAFLD) is now the term used for hepatic steatosis in patients who are overweight or obese, have type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. The prevalence of MAFLD among morbidly obese subjects is 65–93%. Hepatic dendritic cells (hDCs) are antigen-presenting cells that induce T cell-mediated immunity. MAFLD pathogenesis involves numerous immune cell-mediated inflammatory processes, while the particular role of hDCs is yet to be well defined. This study aimed to identify hDCs in liver biopsies from 128 patients with MAFLD associated with obesity. In this cross-sectional study, 128 liver biopsies from 128 patients with MAFLD (diagnosed as presence of hepatic steatosis, plus T2DM, metabolic dysregulation or overweight/obesity) were collected and assessed for CD11c+ immunoreactivity degree (CD11c as dendritic cell biomarker), through antigen retrieval, reaction with CD11c antibodies (primary), and marking with diaminobenzidine chromogen. Among the 128 patients with MAFLD, 64 (50%) had MAFLD and fibrosis and 72 (56.2%) positively expressed hDCs (CD11c+). Among morbidly obese patients, 49 (64.5%) positively expressed hDCs (CD11c+) in liver tissue; from patients with obesity grade I- grade II (GI–II), 18 (54.5%) positively expressed hDCs (CD11c+) in liver tissue; and from non-obese patients with MAFLD, 5 (26.3%) positively expressed hDCs (CD11c+) in liver tissue. hDC expression increases significantly in morbidly obese patients with MAFLD compared with non-obese patients, independent of the degree of fibrosis, suggesting the role of adaptive changes within hDCs in the perpetuation of inflammatory insults in chronic liver diseases.
- 8 August 2022
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 28, e937528-1-e937528-11
Open AccessIdentification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity
Metabolic dysfunction-associated fatty liver disease (MAFLD) is now the term used for hepatic steatosis in patients who are overweight or obese, have type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. The prevalence of MAFLD among morbidly obese subjects is 65–93%. Hepatic dendritic cells (hDCs) are antigen-presenting cells that induce T cell-mediated immunity. MAFLD pathogenesis involves numerous immune cell-mediated inflammatory processes, while the particular role of hDCs is yet to be well defined. This study aimed to identify hDCs in liver biopsies from 128 patients with MAFLD associated with obesity. In this cross-sectional study, 128 liver biopsies from 128 patients with MAFLD (diagnosed as presence of hepatic steatosis, plus T2DM, metabolic dysregulation or overweight/obesity) were collected and assessed for CD11c+ immunoreactivity degree (CD11c as dendritic cell biomarker), through antigen retrieval, reaction with CD11c antibodies (primary), and marking with diaminobenzidine chromogen. Among the 128 patients with MAFLD, 64 (50%) had MAFLD and fibrosis and 72 (56.2%) positively expressed hDCs (CD11c+). Among morbidly obese patients, 49 (64.5%) positively expressed hDCs (CD11c+) in liver tissue; from patients with obesity grade I- grade II (GI–II), 18 (54.5%) positively expressed hDCs (CD11c+) in liver tissue; and from non-obese patients with MAFLD, 5 (26.3%) positively expressed hDCs (CD11c+) in liver tissue. hDC expression increases significantly in morbidly obese patients with MAFLD compared with non-obese patients, independent of the degree of fibrosis, suggesting the role of adaptive changes within hDCs in the perpetuation of inflammatory insults in chronic liver diseases.
- Open Access
- 23 September 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-4
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland
Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are histologically similar to Ductal Breast Cancer. We report what we believe to be the first case in literature of metastatic salivary duct carcinoma (SDC) of the parotid gland with objective response to tamoxifen and aromatase inhibitors, achieving a long-term stability of disease with no associated toxicity. A 70-year-old female was referred to our institution for treatment of a painless nodular lesion in the scalp, localized in the frontal region of the cranium. A biopsy was taken and tested positive for metastatic ductal carcinoma. On PET CT hypermetabolic nodules were localized in the left parotid gland (11 mm), right parotid gland (10 and 12 mm), submandibular node (11 mm) and left cervical node (10 mm). A salivary ductal carcinoma was considered to be the primary tumor. The patient was subsequently started on tamoxifen, with a complete response from the scalp nodule and left parotid nodule, while the right parotid nodule demonstrated a partial response that maintained stable for 2 years until progression. Anastrazol was chosen as the next line of treatment, achieving 6 more months of stable disease. As a pseudo-adjuvant treatment, surgical resection of the right parotid lesion was performed and helped achieve two years of disease stability. Estrogen receptor antagonists such as tamoxifen or aromatase inhibitors may represent a target for the establishment of a safe alternative and novel therapy for SDC, however more accurate data obtained from larger studies are required.
- 23 September 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 1-4
Open AccessCase report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland
Ductal carcinomas of the parotid gland are rare, highly aggressive, have a poor prognosis and are histologically similar to Ductal Breast Cancer. We report what we believe to be the first case in literature of metastatic salivary duct carcinoma (SDC) of the parotid gland with objective response to tamoxifen and aromatase inhibitors, achieving a long-term stability of disease with no associated toxicity. A 70-year-old female was referred to our institution for treatment of a painless nodular lesion in the scalp, localized in the frontal region of the cranium. A biopsy was taken and tested positive for metastatic ductal carcinoma. On PET CT hypermetabolic nodules were localized in the left parotid gland (11 mm), right parotid gland (10 and 12 mm), submandibular node (11 mm) and left cervical node (10 mm). A salivary ductal carcinoma was considered to be the primary tumor. The patient was subsequently started on tamoxifen, with a complete response from the scalp nodule and left parotid nodule, while the right parotid nodule demonstrated a partial response that maintained stable for 2 years until progression. Anastrazol was chosen as the next line of treatment, achieving 6 more months of stable disease. As a pseudo-adjuvant treatment, surgical resection of the right parotid lesion was performed and helped achieve two years of disease stability. Estrogen receptor antagonists such as tamoxifen or aromatase inhibitors may represent a target for the establishment of a safe alternative and novel therapy for SDC, however more accurate data obtained from larger studies are required.